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Maternal psychiatric disease and epigenetic
evidence suggest a common biology for
poor fetal growth
Timothy H. Ciesielski3,4*, Carmen J. Marsit1,2 and Scott M. Williams3,4
Abstract
Background: We sought to identify and characterize predictors of poor fetal growth among variables extracted
from perinatal medical records to gain insight into potential etiologic mechanisms. In this process we reevaluated a
previously observed association between poor fetal growth and maternal psychiatric disease.
Methods: We evaluated 449 deliveries of >36 weeks gestation that occurred between 9/2008 and 9/2010 at the
Women and Infants Hospital in Providence Rhode Island. This study group was oversampled for Small-for-
Gestational-Age (SGA) infants and excluded Large-for-Gestational-Age (LGA) infants. We assessed the associations
between recorded clinical variables and impaired fetal growth: SGA or Intrauterine Growth Restriction (IUGR)
diagnosis. After validating the previously observed association between maternal psychiatric disease and impaired
fetal growth we addressed weaknesses in the prior studies by explicitly considering antidepressant use and the
timing of symptoms with respect to pregnancy. We then evaluated DNA methylation levels at 27 candidate loci in
placenta from a subset of these deliveries (n = 197) to examine if epigenetic variation could provide insight into the
mechanisms that cause this co-morbidity.
Results: Infants of mothers with prenatal psychiatric disease (Depression, Anxiety, OCD/Panic) had increased
odds of poor fetal growth (ORadjusted = 3.36, 95%CI: 1.38-8.14). This relationship was similar among those who
were treated with antidepressants (ORadjusted = 3.69, 95%CI: 1.31-10.45) and among those who were not
(ORadjusted = 3.19, 95%CI: 1.30-7.83). Among those with a history of psychiatric disease but no active disease in
pregnancy the ORadjusted was 0.45 (95%CI: 0.09-2.35). A locus near the transcription start site of the leptin
receptor (cg21655790) had methylation levels that were decreased in the presence of: 1) SGA/IUGR, and 2)
active but not resolved psychiatric disease (among mothers not on antidepressants).
Conclusions: These results validate and further characterize the association between maternal psychiatric
disease and poor fetal growth. Because the association appears to depend on active psychiatric disease, this
suggests a transient and potentially modifiable pathophysiology. The molecular findings in this study suggest
that altered leptin signaling may be involved in the biological mechanisms that link prenatal maternal
psychiatric symptoms and poor fetal growth.
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Background
Several epidemiologic studies have evaluated links be-
tween antenatal maternal psychiatric disease and poor
fetal growth. While the majority of reports have focused
on depression (reviewed in [1–3]), other conditions such
as bipolar disorder [4, 5], panic disorder [6, 7], and mental
illness as a whole [8] have also been assessed. Unfortu-
nately, as a group, the existing studies of maternal psy-
chiatric disease and poor fetal growth are difficult to
interpret because of ambiguous or non-comparable
fetal growth outcomes (e.g. Low-Birth-Weight [LBW]
vs. Small-for-Gestational-Age [SGA]) and inconsistent
findings. It is also largely unclear if poor fetal growth is
associated with the experience of psychiatric symptoms
during pregnancy or other characteristics of mothers
with psychiatric diagnoses whether they are symptom-
atic in pregnancy or not. An additional complication is
that observational studies are limited in their ability to
separate associations with psychiatric disease from
associations with psychiatric medication. Despite these
difficulties, evaluating associations with clinical psy-
chiatric diagnoses is important because other psycho-
social variables that have been associated with poor
fetal growth [9–11] may not be available in medical
records, and thus have limited potential to inform ob-
stetrical care.
Identifying predictors of poor fetal growth is key to find-
ing etiologic subtypes and defining homogeneous groups
for pathophysiologic study. Perinatal medical records can
provide a rich source of potential predictors for distinguish-
ing these subtypes. In this study we analyzed a sample of
449 mother-infant pairs to identify and characterize clinical
predictors of poor fetal growth, and in this process we re-
evaluated the association between prenatal maternal psychi-
atric disease and poor fetal growth. These analyses address
some weaknesses in the prior studies by utilizing medically
interpretable outcomes (SGA and Intrauterine Growth
Retardation [IUGR]), considering the timing of psychiatric
diagnosis with respect to pregnancy, and evaluating anti-
depressant treated and untreated mothers separately. We
also present an exploratory analysis of placental DNA
methylation patterns to examine biological factors that may
be involved in the pathophysiology linking maternal psychi-
atric symptoms to poor fetal growth.
Methods
Data source and study group
A structured form was used to abstract perinatal clinical
information from the medical records of 490 deliveries
that occurred between September 2008 and September
2010 at the Women and Infants Hospital in Providence
Rhode Island. Eligible deliveries were from pregnancies
of ≥36 weeks gestation that resulted in viable infants and
were not complicated by diagnosed preeclampsia or known
fetal genetic conditions.
The primary objective of this parent cohort was to
examine how epigenetic features of the placenta were
related to growth restriction. In order to improve power
and efficiency, infants considered small for gestational
age were over-represented within the sample. Infants not
considered SGA were then selected to match the SGA in-
fants on sex, maternal age (within 3 years), and gestational
age (within 1 week). The study procedures were approved
by the Institutional Review Boards of the Women and
Infants Hospital, Brown University, and the Committee
for Protection of Human Subjects at Dartmouth College.
A waiver of consent was obtained through approval of the
Women and Infants Hospital IRB. Samples and data were
collected in a de-identified fashion.
For the analysis, SGA was defined as <10th percentile
for birth weight based on the 2003 Fenton infant growth
chart [12] and IUGR was as noted in the medical records
(typically: sonographic measurements estimating <10th
percentile for weight based on gestational age [13]). Poor
fetal growth was defined as the presence of SGA, IUGR,
or both. Large for Gestational Age (LGA, >90th percentile
for birth weight) deliveries were excluded from the
analyses (n = 41), leaving a study group of 449 deliveries.
This clarified the comparisons being made by including
only AGA infants in the reference group (i.e. we were
interested in comparing SGA and AGA infants, not SGA
and a mixture of AGA and LGA infants). Maternal psychi-
atric status was recorded as the presence of Depression,
Anxiety, or OCD/Panic disorder in pregnancy and history
of Depression, Anxiety, or OCD/Panic disorder at any
time (not necessarily during pregnancy).
DNA methylation data
Epigenetic analyses were conducted using placenta from
a subset of deliveries (n = 197). Placental samples were
obtained within 2 h of delivery, and DNA methylation
levels were measured using the Human-Methylation-27
BeadChip array (Illumina Inc., San Diego, CA). Details
of these protocols have been previously described [14].
Statistical analyses
Logistic Regression was used to determine the un-
adjusted associations between the clinical variables and
SGA/IUGR status. Differences in the distributions of
clinical and outcome variables (SGA/IUGR) by mater-
nal psychiatric status were determined by Wilcoxon-
Mann–Whitney, Chi-square, or Fisher’s exact tests as
appropriate. Crude and adjusted logistic regression
models were used to estimate the association between
maternal psychiatric disease in pregnancy and poor
fetal growth (SGA/IUGR). Models were adjusted for
variables that may confound the relationship between
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maternal psychiatric disease and poor fetal growth based
on subject matter knowledge.
We evaluated for differences in the distribution of
participant characteristics between those with placental
methylation data and those without using Wilcoxon-
Mann–Whitney, Chi-Square, and Fisher’s Exact tests as
appropriate (Additional file 1: Table S12). Candidate methy-
lation loci were identified through a literature and locus
annotation search described in the supplemental materials
(Additional file 1). Briefly: We identified a recent paper that
listed genes linked to poor fetal growth [15]. These genes
were often implicated by association with variants within
the gene or their differential expression patterns. Subse-
quent investigation of these genes lead to the identification
of other genes linked to SGA/IUGR, and the hits from
Banister et al. [14] were also evaluated. We then scanned
OMIM (http://www.ncbi.nlm.nih.gov/omim) and Pubmed
(http://www.ncbi.nlm.nih.gov/pubmed/) for evidence link-
ing these genes to psychiatric disease. This process identi-
fied 11 genes with links to both SGA/IUGR and psychiatric
disease (Additional file 1: Table S3). One imprinted gene,
MEG3 (Maternally Expressed Gene 3) [16, 17], was ex-
cluded because methylation measurements at imprinted
genes could be unreliable on the Illumina 27 K array plat-
form, as the targeted loci may not be in the imprinting
control region. Then we performed texts searches for
these 10 genes in the annotation file for the Human-
Methylation-27 BeadChip array (Illumina Inc., San Diego,
CA) and identified 27 loci with annotations that related to
these genes (Additional file 1: Table S4).
Logistic regression was used to determine if any of these
27 loci had methylation patterns that were significantly
associated with SGA/IUGR or psychiatric diagnosis (false
discovery rate [FDR] adjusted p-value < 0.05). For the loci
with methylation patterns that differed by SGA/IUGR
status, Fisher’s exact tests (FDR adjusted) were used to
determine if methylation status (above vs. below median)
differed between these three categories: 1) no psychiatric
diagnosis and no antidepressant, 2) psychiatric diagnosis
and no antidepressant, 3) psychiatric diagnosis and anti-
depressant). Exact binomial tests within these 3 strata (FDR
adjusted) were conducted to determine if any of the strata
had a significant excess of above or below median methyla-
tion values. After excluding women on antidepressants, a
similar approach was used to evaluate associations separ-
ately among those with active psychiatric disease, resolved
psychiatric disease, and no history of psychiatric disease.
We also evaluated if other measured factors differed be-
tween those with no psychiatric disease, un-medicated psy-
chiatric disease and medicated psychiatric disease (Kruskal-
Wallis or Fisher’s Exact tests as appropriate, Additional
file 1: Table S8). Mean methylation levels were also calcu-
lated (Additional file 1: Table S6 and S7). Analyses were
conducted using SAS 9.1.3 (SAS Institute Inc., Cary, NC).
Results
Characteristics of the study group are presented in
Table 1. The study group was oversampled for SGA
deliveries and excluded LGA deliveries. 155 out of the
449 (34.5 %) had evidence of impaired fetal growth
(SGA or IUGR diagnosis or both). Infant sex was evenly
divided (50.3 % male, 49.7 % female), and the mothers
represent a group that is oversampled for non-white race
compared the Rhode Island population in general based
on the 2010 census [18].
In unadjusted logistic regression analyses, prenatal ma-
ternal depression (OR = 3.90, 95 % CI: 2.06-7.36, n = 46),
anxiety (OR = 3.15, 95 % CI: 1.51-6.57, n = 32), and OCD/
Panic disorders (OR = 8.23, 95 % CI: 1.73-39.26, n = 10)
were associated with poor fetal growth, as was prenatal
maternal psychiatric disease as a whole (depression, anx-
iety, or OCD/Panic, OR = 3.93, 95 % CI: 2.21-6.98, n = 58).
Logistic regression analyses for additional clinical variables
are presented in Additional file 1: Table S1. The associa-
tions with these prenatal psychiatric variables remained
significant after accounting for multiple testing (FDR
adjusted p-values, prenatal depression: 6.7 × 10−04, prenatal
anxiety: 1.1 × 10−02, prenatal OCD/Panic: 3.0 × 10−02, and
prenatal psychiatric disease: 1.4 × 10−04) and the p-values
for prenatal depression and prenatal psychiatric disease
were the two smallest in Additional file 1: Table S1. Of
participants who had a psychiatric diagnosis in pregnancy,
62 % (36/58) had poor fetal growth, while 29 % (112/381)
of the remaining participants had poor fetal growth.
Women with prenatal psychiatric diagnoses were more
likely to use tobacco and antidepressant medication,
and they also differed with respect to insurance type, a
crude measure of socioeconomic status (Fisher’s exact
tests p < 0.05). 64 % of women with prenatal psychi-
atric diagnoses had public insurance compared to
43 % of women without prenatal psychiatric diagnoses.
Additional information on covariate distributions by
maternal psychiatric status are available in Additional
file 1: Table S2.
The association between maternal psychiatric diagnosis
in pregnancy and poor fetal growth remained significant
after adjusting for: antidepressant medication use, tobacco
use, alcohol use, recreational drug use, first pregnancy vs.
not first pregnancy, race (white, black, Asian, or other
race/unknown), insurance (public, private, military, self-
pay), maternal age (<20, 20–34, and >34 years), maternal
height, and maternal weight (ORadjusted = 3.36, 95 % CI:
1.38-8.14, Table 2). Adjusted ORs for poor fetal growth
were similar among the specific diagnoses evaluated here:
Depression, Anxiety, and OCD/Panic (Table 3). The odds
of poor fetal growth were increased with psychiatric diag-
nosis regardless of whether the mother was on antidepres-
sant medication (ORadjusted = 3.69, 95 % CI: 1.31-10.45) or
not (ORadjusted = 3.19, 95 % CI: 1.30-7.83, Table 4). Among
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women with a history of psychiatric diagnosis, the odds of
poor fetal growth were only increased only if they had ac-
tive disease in pregnancy (active disease ORadjusted = 2.87,
95 % CI: 1.15-7.20, resolved disease ORadjusted = 0.45, 95 %
CI: 0.09-2.35, Table 5).
DNA methylation analyses using the Illumina Infinium
27 K array were performed on placenta from a subset of
197 participants. In this subset there were 89 subjects
with SGA/IUGR and 26 with psychiatric diagnosis.
Those included in the methylation analyses were similar
to those excluded from the methylation analyses (Add-
itional file 1: Table S12) but the number of previous
preterm births was slightly higher among those included
(mean: 0.20, standard deviation: 0.61 vs. mean: 0.10,
standard deviation: 0.35; Wilcoxon test p = 5.0x10−02).
When examining 27 candidate loci from 15 genes, 6 loci
had placental DNA methylation levels that were signifi-
cantly associated with SGA/IUGR status but no loci
had methylation levels that were significantly associated
with psychiatric status (FDR adjusted p-values <0.05).
These 6 loci were located near the transcription start
sites of 5 genes: FKBP5, RPE65, LEPR, LEPROTL1,
NFKBIZ (2 methylation sites for NFKBIZ). Odds of poor
fetal growth increased with higher methylation at FKBP5/
cg08636224 and RPE65/cg11724759 and decreased with
higher methylation at LEPR/cg21655790, LEPROTL1/
cg00177923, and NFKBIZ /cg26284390/cg15006396 (de-
tails in Additional file 1: Table S5).
To assess if antidepressant use might be masking rela-
tionships between psychiatric disease and methylation
status we evaluated methylation levels within strata
defined by both psychiatric diagnosis and antidepressant
medication use (i.e. no psychiatric diagnosis, psychiatric
diagnosis on antidepressants, and psychiatric diagnosis
not on antidepressants). Given the low numbers of
participants in some of these strata, we used Fisher’s
exact tests to determine if methylation status (above vs.
below median) differed between the three groups for
each of the 6 loci (Table 6; mean methylation levels are
presented in Supplemental Table 6 in Additional file 1).
These analyses revealed that methylation at LEPR/
cg21655790, a locus near the transcription start site of
Table 1 Characteristics of the 449 mother-infant pairs in the
study group
Median IQR
Maternal age in years 28 24 - 32
Maternal height in cm (98 missing) 160 157 - 165
Maternal weight in kg (93 missing) 63.3 55.5 - 75.0






Other race or unknown 115 25.6
Hypertension in pregnancy (2 missing)
No 420 94.0
Yes 27 6.0
Diabetes in pregnancy (2 missing)
No 430 96.2
Yes 17 3.8
Tobacco in pregnancy (2 missing)
No 399 89.3
Yes 48 10.7
Alcohol in pregnancy (1 missing)
No 445 99.3
Yes 3 0.7
Recreational drugs in pregnancy (3 missing)
No 436 97.8
Yes 10 2.2
















First pregnancy (3 missing)
No 284 63.7
Yes 162 36.3
Table 1 Characteristics of the 449 mother-infant pairs in the
study group (Continued)







aDepression, Anxiety, or OCD/Panic disorder in pregnancy
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the leptin receptor, differed between the three strata
(Fisher’s exact test: FDR adjusted p = 0.029). Three
follow-up exact binomial tests revealed that those with
psychiatric diagnosis and no antidepressant medication
were more likely to have below median placental methyla-
tion at LEPR/cg21655790 (FDR adjusted p = 0.01). Fur-
thermore, among those not on antidepressants, placental
methylation at this locus differed between the following 3
groups: 1) those with no history of psychiatric disease, 2)
those with a history but no active disease, and 3) those
with a history and active disease (Table 7, Fisher’s exact
test p = 4.8 × 10−4, mean methylation levels are presented
in Supplemental Table 7 in Additional file 1). Follow-up
exact binomial tests in these three groups revealed that
only those with active psychiatric diagnosis were more
likely to have below median placental methylation at
LEPR/cg21655790 (FDR adjusted p = 0.01).
We also evaluated if other factors differed between the 3
psychiatric status categories from Table S7, to identify if
additional measured factors were related to maternal
psychiatric disease (Additional file 1: Table S8). Prenatal
tobacco use was associated with active un-medicated psy-
chiatric disease (Fisher’s Exact test p = 3.0 × 10−3), and also
demonstrated a non-significant relationship with below
median placental methylation at LEPR/cg21655790 (Fisher’s
exact test p = 1.3 × 10−1 see Additional file 1: Table S9).
The association between un-medicated psychiatric disease
and decreased methylation at LEPR/cg21655790 is still
significant when those with prenatal tobacco use are ex-
cluded from the analysis (Fisher’s exact test: p = 3.3 × 10−2,
Additional file 1: Table S10), and the association between
decreased methylation at LEPR/cg21655790 and poor fetal
growth still significant in a logistic regression model
Table 2 Odds Ratios for poor fetal growth associated with
active maternal psychiatric diagnosis
OR 95 % CI p-value
Unadjusted 3.93 2.21–6.98 3.0 × 10−06
Adjusteda 3.36 1.38–8.14 7.4 × 10−03
aAdjusted for antidepressant medication, tobacco use, alcohol use, recreational
drug use, first pregnancy vs. not first pregnancy), race (white, black, Asian, or
other race/unknown), insurance (public, private, military, self-pay), maternal
age (<20, 20–34, and >34 years), maternal height, and maternal weight
Table 3 Odds Ratios for poor fetal growth by specific maternal
psychiatric diagnoses
OR 95 % CI p-value
Depression in pregnancy
(n = 46)
Unadjusted 3.90 2.06–7.36 2.8 × 10−05
Adjusteda 2.86 1.02–8.05 4.6 × 10−02
Anxiety in pregnancy
(n = 32)
Unadjusted 3.15 1.51–6.57 2.2 × 10−03
Adjusteda 2.94 1.09–7.97 3.4 × 10−02
OCD or panic disorder
in pregnancy (n =10)b
Unadjusted 8.23 1.73–39.26 8.2 × 10−03
Adjusteda 2.74 0.46–16.49 2.7 × 10−01
aAdjusted for antidepressant medication, tobacco use, alcohol use, recreational
drug use, first pregnancy vs. not first pregnancy, race (white, black, Asian, or
other race/unknown), insurance (public, private, military, self-pay), maternal
age (<20, 20–34, and >34 years), maternal height, and maternal weight
bThe effect estimate precision in this category is very low due to a small n, but
the direction of association is consistent with the other two diagnoses
Table 4 Odds Ratios for poor fetal growth associated with
medicated and un-medicated maternal psychiatric diagnosis
ORa 95 % CI p-value
Unadjusted
Psychiatric diagnosis with
no antidepressant use (n =36)
4.05 2.00–8.24 1.1 × 10−04
Psychiatric diagnosis with
antidepressant use (n =19)




3.19 1.30–7.83 1.1 × 10−02
Psychiatric diagnosis with
antidepressant use
3.69 1.31–10.45 1.4 × 10−02
aReference is those with no psychiatric diagnosis and no antidepressant
medication use (n =358). Note: there was 1 participant on antidepressant
medication with no reported psychiatric diagnosis in pregnancy but this group
was too small to evaluate here
bAdjusted for tobacco use, alcohol use, recreational drug use, first pregnancy
vs. not first pregnancy, race (white, black, asian, or other race/unknown),
insurance (public, private, military, self-pay), maternal age (<20, 20–34,
and >34 years), maternal height, and maternal weight
Table 5 Odds Ratios for poor fetal growth by the timing of
maternal psychiatric diagnosis
ORa 95 % CI p-value
Unadjusted
History of psychiatric diagnosis but
no active diagnosis during pregnancy
(n = 18)
0.93 0.32–2.67 8.9 × 10−01
History of Psychiatric diagnosis and
active diagnosis during pregnancy
(n = 56)
3.73 2.09–6.68 9.2 × 10−06
Adjustedb
History of Psychiatric diagnosis but
no active diagnosis during pregnancy
(n = 10)
0.45 0.09–2.35 3.4 × 10−01
History of Psychiatric diagnosis and
active diagnosis during pregnancy
(n = 42)
2.87 1.15–7.20 2.4 × 10−02
aReference is those with no recorded history of ever having Depression,
Anxiety, or OCD/Panic disorder (n = 362). Note: there were 2 people with
newly reported psychiatric diagnosis in pregnancy and no prior history of
psychiatric diagnosis but this group was too small to evaluate here
bAdjusted for antidepressant medication, tobacco use, alcohol use, recreational
drug use, first pregnancy vs. not first pregnancy, race (white, black, asian, or
other race/unknown), insurance (public, private, military, self-pay), maternal
age (<20, 20–34, and >34 years), maternal height, and maternal weight
Ciesielski et al. BMC Pregnancy and Childbirth  (2015) 15:192 Page 5 of 9
adjusted for prenatal tobacco use (p = 8.5 × 10−3, Additional
file 1: Table S11).
Discussion
Our analyses validate and further characterize previously
observed associations [1, 3, 6, 8] between maternal psy-
chiatric disease and poor fetal growth. In these data,
mothers with evidence of prenatal psychiatric disease
(Depression, Anxiety, OCD/Panic) had increased odds of
having a pregnancy with poor fetal growth (IUGR/SGA).
This relationship was similar regardless of whether the
women were treated with antidepressants or not. The find-
ings among antidepressant treated mothers are difficult to
interpret because it is hard to separate associations with
medication use from associations with psychiatric disease.
Additionally, a direct comparison of the ORs from the
antidepressant treated and untreated groups is not very
informative because medication was not allocated randomly
(e.g. those on antidepressants may have had more severe
disease). However the results among untreated mothers,
are not affected by these complications, and they suggest
an independent association between psychiatric disease and
poor fetal growth. We did not detect any evidence for an
association, or even a similar trend, among women with
resolved disease, but we had limited power to do so. Taken
together these results suggest that the association is driven
by transient and thus potentially modifiable factors.
The remaining analyses explored DNA methylation
patterns in placentae from a subset of these deliveries to
identify biological factors that could be involved in the
pathophysiology that links maternal psychiatric disease
and poor fetal growth. The results of the initial epide-
miologic analyses were used to guide these exploratory
analyses because they led to several predictions about
Table 6 Methylation at 6 candidate loci within strata defined by psychiatric and medication status













59/159 (37.1 %) 10/13 (76.9 %) 9/12 (75.0 %)
had SGA or IUGR had SGA or IUGR had SGA or IUGR
FKBP5 <= Median 79 (49.7 %) 4 (30.8 %) 8 (66.7 %) 3.7 × 10−01
cg08636224 > Median 80 (50.3 %) 9 (69.2 %) 4 (33.3 %)
RPE65 <= Median 85 (53.5 %) 4 (30.8 %) 6 (50.0 %) 3.7 × 10−01
cg11724759 > Median 74 (46.5 %) 9 (69.2 %) 6 (50.0 %)
LEPRa <= Median 76 (47.8 %) 12 (92.3 %) 5 (41.7 %) 2.9 × 10−02
cg21655790 > Median 83 (52.2 %) 1 (7.7 %) 7 (58.3 %)
LEPROTL1 <= Median 80 (50.3 %) 6 (46.2 %) 3 (25.0 %) 3.7 × 10−01
cg00177923 > Median 79 (49.7 %) 7 (53.9 %) 9 (75.0 %)
NFKBIZ <= Median 76 (47.8 %) 11 (84.6 %) 6 (50.0 %) 1.1 × 10−01
cg26284390 > Median 83 (52.2 %) 2 (15.4 %) 6 (50.0 %)
NFKBIZ <= Median 80 (50.3 %) 8 (61.5 %) 5 (41.7 %) 6.5 × 10−01
cg15006396 > Median 79 (49.7 %) 5 (38.5 %) 7 (58.3 %)
aMethylation at LEPR/cg21655790 differs significantly between these three categories (Fisher’s exact test: FDR adjusted p = 0.029). Three follow up tests (exact
binomial tests that p = 0.5) revealed that those with psychiatric diagnosis and no antidepressant medication are more likely to have below median placental
methylation at LEPR/cg21655790 (FDR adjusted p = 0.01). NFKBIZ/cg26284390 has a very similar pattern of results as LEPR/cg21655790 but it misses significance in
the Fisher’s exact test (FDR adjusted p = 0.107)
Table 7 Methylation at the leptin receptor locus by timing of psychiatric diagnosis among those not on antidepressant medication
Gene and locus Methylation
(adjusted Beta)
No History of Psychiatric




Diagnosis but no Active
Psychiatric Diagnosis (n = 8)
History of Psychiatric Diagnosis




57/151 (37.8 %) 2/8 (25.0 %) 10/13 (76.9 %)
had SGA or IUGR had SGA or IUGR had SGA or IUGR
LEPRa <= Median 75 (49.7 %) 1 (12.5 %) 12 (92.3 %) 4.8 × 10−4
cg21655790 > Median 76 (50.3 %) 7 (87.5 %) 1 (7.7 %)
aMethylation differs between these three categories (Fisher’s exact test p = 4.8 x 10−4). Three follow up tests (exact binomial tests that p = 0.5) revealed that those
with active maternal psychiatric diagnoses are more likely to have below median placental methylation at LEPR/cg21655790 (FDR adjusted p = 0.01)
bAs noted in Table 5, there were 2 people with no prior history of psychiatric diagnosis who had newly reported psychiatric diagnosis in pregnancy. Neither of
these participants had LEPR/cg2165570 methylation data
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the features that etiologically relevant methylation pat-
terns might have. If placental methylation at any locus
was involved in this shared pathophysiology then methy-
lation levels at this locus should be associated with both
poor fetal growth and maternal psychiatric disease, and
the direction of association should be the same for both
phenotypes. In addition, the association should be present
in active but not resolved disease. One of the 27 loci,
LEPR/cg21655790, had methylation patterns that were
consistent with all of these predictions. This suggests that
decreased placental DNA methylation near the leptin
receptor locus (cg21655790) may be involved with the bio-
logical processes that result in poor fetal growth in women
with active psychiatric disease.
We were also able to strengthen our findings by
conducting additional analyses to explore alternative
explanations for this pattern in the methylation data
(Additional file 1: Tables S8–S11). In these additional
analyses we found that prenatal tobacco use was signifi-
cantly associated with active psychiatric disease and was
non-significantly associated with decreased methylation
at LEPR/cg21655790. However, after accounting for
prenatal tobacco use, the associations between LEPR/
cg21655790 methylation and 1) un-medicated psychi-
atric disease, and 2) poor fetal growth were both still
significant. Furthermore, the association between active
psychiatric disease and poor fetal growth was still signifi-
cant after adjusting for prenatal tobacco use. In sum,
even though tobacco use frequently occurs with prenatal
psychiatric disease, the links between active psychiatric
disease, poor fetal growth, and decreased methylation at
the LEPR locus are not explained by prenatal tobacco use.
Leptin is an endocrine signaling molecule that has
an established role in regulating energy use and nutri-
tional intake [19], but it appears to also play a role in
the pathophysiology of depression and anxiety. Obser-
vational studies in humans suggest that depression is
associated with decreased circulating leptin levels
(reviewed briefly in [20, 21]), however, there have been
some inconsistencies between the studies [22–28]. It
has been suggested that complicating factors such as
leptin sensitivity may help to explain these discrepan-
cies and that leptin levels may only be decreased in a
subset of depressed patients [20, 21]. Defining and
characterizing this putative subgroup may help to
advance our understanding of the association between
depression and poor fetal growth. In addition to these
findings with depression, lower serum leptin levels in
women have been associated with anxiety symptoms
and perceived stress [26].
Disrupted leptin signaling is also implicated in poor
fetal growth as evidence suggests that growth impaired
pregnancies are characterized by altered leptin physi-
ology in cord blood [29–31], placenta [32, 33], and
maternal serum [34], although reports on maternal serum
have varied in designs and results [34–43]). Additionally,
laboratory studies (reviewed in [44]) demonstrate that lep-
tin plays a key role in promoting placental trophoblast
proliferation and survival.
Overall it appears that leptin plays important roles in 1)
the regulation of nutritional intake and energy balance, 2)
the physiology of depression and anxiety, and 3) the
orchestration of fetal nutritional intake and growth. This
pleiotropy in leptin function may allow us to identify a
subgroup of pregnancies (those complicated by depres-
sion or anxiety disorders) that may be at increased risk
of poor fetal growth due to a mechanism that involves
altered leptin signaling. Future research should aim to
validate and further characterize the link between poor
fetal growth and leptin signaling.
To our knowledge this is the first report linking placental
LEPR/cg21655790 methylation levels to active maternal
psychiatric disease and poor fetal growth. We are not aware
of any specific evidence in the literature which suggests that
a change in placental LEPR/cg21655790 methylation would
alter placental leptin receptor expression levels or function
in pregnancy. However there is evidence from other tissues
that links altered leptin receptor methylation in to changes
in leptin receptor expression and functional changes in
leptin signaling. Experiments in mice suggest that a high fat
diet in late gestation can result in increased methylation at
CPG sites near the leptin receptor in visceral fat of the
offspring and decreased leptin receptor expression (mRNA)
in this same tissue [45]. These changes are tissue specific,
and are not observed in skeletal muscle. Additionally, the
mice exposed to this high fat late gestational diet (which
appears to increase methylation at the leptin receptor gene
in visceral fat) also exhibited increased food/calorie intake
and faster increases in body weight in the first 20 weeks of
life. Thus although we cannot cite papers that demonstrate
the physiologic importance of LEPR/cg21655790 methyla-
tion in placenta, there is evidence from other tissues which
suggests that methylation changes near the leptin receptor
gene may have functional consequences.
We recognize that this study has both weaknesses and
strengths that are worthy of mention. In terms of weak-
nesses, this analysis was not based on a random sample
and it is possible that those who were included were in
some way not ideally representative of the source popu-
lation. We also note that we had limited sample sizes in
the strata defined by psychiatric status and antidepressant
use. Nonetheless we detected significant associations within
these small strata. As in any observational study the poten-
tial for unrecognized bias or uncontrolled confounding
cannot be ruled out, but the associations with maternal
psychiatric disease were robust to adjustment for several
potential confounders. We also note a number of strengths
with our study. We were able to validate and further
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characterize a previously observed association that should
provide insight into the etiologies of poor fetal growth. Our
epidemiologic characterization then allowed us to make
predictions about the biological factors that may be in-
volved, and we were able to screen available epigenetic
data to find a biological factor that met these predic-
tions. This non-traditional strategy for DNA methyla-
tion analysis may have utility in other settings where
genome-wide methylation measurements have been
made in physiologically relevant tissue.
Conclusions
In this work we validate and further characterize the
association between maternal psychiatric symptoms
and poor fetal growth. We found that mothers who
experienced active depression or anxiety in pregnancy
were more likely to deliver SGA/IUGR infants, and
our follow-up epigenetic analyses suggest that altered
leptin signaling may be involved in the biologic mech-
anisms that cause these maternal and fetal pathologies
to co-occur. This work is important because depression
and anxiety are very common conditions in pregnancy
(about 7-20 % for depression [46, 47] and 8-15 % for anx-
iety [48]) and thus the pathophysiology associated with
these conditions may be responsible for a large proportion
of SGA births. Determining the causes of poor fetal
growth is a fundamental public health goal because it is
associated with both perinatal morbidity and variety of
lifelong health problems such as cardiovascular disease,
type II diabetes, and impaired neurocognition [49–51].
The associations reported here between psychiatric disease,
leptin physiology, and poor fetal growth do not necessarily
reflect causal relationships, but determining the underlying
factors that link them should help to identify modifiable
causes of poor fetal growth. Additional validation and
characterization of these associations may eventually allow
us develop interventions that can safely improve the well-
being of both the mother and the developing child.
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